8,177 Shares in Anika Therapeutics Inc (NASDAQ:ANIK) Bought by WINTON GROUP Ltd

WINTON GROUP Ltd bought a new position in Anika Therapeutics Inc (NASDAQ:ANIK) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 8,177 shares of the biotechnology company’s stock, valued at approximately $332,000. WINTON GROUP Ltd owned 0.06% of Anika Therapeutics as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Quantamental Technologies LLC bought a new position in Anika Therapeutics in the 1st quarter worth $69,000. BNP Paribas Arbitrage SA raised its holdings in Anika Therapeutics by 356.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,891 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 2,257 shares during the period. Municipal Employees Retirement System of Michigan bought a new position in Anika Therapeutics in the 4th quarter worth $140,000. Metropolitan Life Insurance Co. NY raised its holdings in Anika Therapeutics by 382.3% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 5,141 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 4,075 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Anika Therapeutics by 99.8% in the 1st quarter. SG Americas Securities LLC now owns 6,477 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 3,235 shares during the period. 93.93% of the stock is currently owned by institutional investors.

NASDAQ:ANIK traded up $0.35 on Friday, reaching $55.15. 13,276 shares of the company’s stock traded hands, compared to its average volume of 239,856. The company has a debt-to-equity ratio of 0.09, a quick ratio of 16.07 and a current ratio of 18.28. The stock’s 50-day moving average is $42.71. The stock has a market capitalization of $755.14 million, a price-to-earnings ratio of 29.97, a PEG ratio of 3.06 and a beta of 1.08. Anika Therapeutics Inc has a 12 month low of $29.01 and a 12 month high of $57.51.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings results on Wednesday, July 24th. The biotechnology company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.25. The business had revenue of $30.42 million for the quarter, compared to analysts’ expectations of $27.41 million. Anika Therapeutics had a return on equity of 11.27% and a net margin of 26.87%. The business’s quarterly revenue was down .4% on a year-over-year basis. During the same period last year, the firm earned $0.68 earnings per share. As a group, sell-side analysts expect that Anika Therapeutics Inc will post 1.75 EPS for the current year.

A number of brokerages recently commented on ANIK. BidaskClub cut Anika Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 16th. TheStreet raised Anika Therapeutics from a “c” rating to a “b-” rating in a report on Friday, July 26th. Barrington Research reaffirmed a “buy” rating and issued a $49.00 target price (up from $45.00) on shares of Anika Therapeutics in a report on Thursday, July 25th. First Analysis raised Anika Therapeutics from a “neutral” rating to a “strong-buy” rating and raised their target price for the stock from $37.00 to $54.00 in a report on Thursday, July 25th. Finally, Zacks Investment Research cut Anika Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 26th. One analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $46.00.

In other Anika Therapeutics news, Director Raymond J. Land sold 3,000 shares of the firm’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $55.44, for a total transaction of $166,320.00. Following the sale, the director now directly owns 11,992 shares of the company’s stock, valued at $664,836.48. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.67% of the stock is owned by company insiders.

About Anika Therapeutics

Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.

See Also: Why do companies pay special dividends?

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.